Tekmira and Collaborators Awarded $2.4 Million NIH Grant for Development of RNAi Therapeutics to Treat Ebola and Marburg Viral Infections

Tekmira Pharmaceuticals Corporation, a leader in RNA interference (RNAi) therapeutics, announced today that, together with collaborators at The University of Texas Medical Branch, it has been awarded a new United States National Institutes of Health (NIH) grant to support research to develop RNAi therapeutics to treat Ebola and Marburg hemorrhagic fever viral infections using Tekmira's lipid nanoparticle (LNP) delivery technology.

Related Posts

Comments are closed.